es 
Medical Directory
More than 500 full time specialists, who guarantee you appropriate care
View Directory
P
U
P
More than 500 full time specialists, who guarantee you appropriate care
View Directory
Target Population
Adult populationThe hematology service of Fundación Valle del Lili is based on principles of quality and excellence and is responsible for treating adult patients with benign and malignant blood diseases. In addition, the service is characterized for its focus on assistance, teaching and research, using top-level technology to ensure adequate and safe results.
The service comprehensively treats patients with malignant diseases, including the most frequent, such as: multiple myeloma, acute and chronic myeloid and lymphoid leukemia, Hodgkin and non-Hodgkin’s lymphomas, myelodysplastic syndromes and others, as well as benign entities such as thrombosis, anemia, thrombocytopenia and coagulation disorders, such as hemophilia, thus providing support and initial treatment until bone marrow transplant procedure.
Assistance processes provided include:
-Multidisciplinary oncology board, hematopathology board, genetics and molecular oncology testing board, bone marrow transplant board.
The hematology service has a high quality staff, with hematology sub-specialist professionals experienced in bone marrow transplantation, as well as in teaching, certified both by our Institution and ICESI university. The whole service receives the help of a comprehensive support team, consisting of general practitioners, nursing staff trained in cancer patient care, psychology and palliative care. Hematologists and specialists in bone marrow transplantation for adult patients:
Why choosing the service?
Fundación Valle del Lili is a high-complexity healthcare institution with widely trained specialists who provide a humanized, comprehensive and excellent care for hematological patients at different stages of the disease.
Novel hematological treatments are available, including: a center of autologous and allogeneic transplants of haematopoietic progenitors for hematological neoplasms requiring it.
